NEW YORK (GenomeWeb) – UK-based liquid biopsy firm Angle said today that it has inked a comarketing agreement with Qiagen for circulating tumor cell (CTC) technology.

Under the terms of the agreement, the companies will market Angle's Parsortix system for harvesting CTCs alongside Qiagen's liquid biopsy product portfolio, including its next-generation sequencing, PCR, single-cell analysis, and bioinformatics products.

The companies will initially focus on prostate and breast cancer research applications, Angle said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.